SUSD2 and cancer: Oxaliplatin uniquely upregulated SUSD2, which is commonly downregulated in CRC and interacts with the potential novel cytokine CSBF/C10orf99 to inhibit CRC cell growth, and SAT1, whose levels are also lower in patients with cancer and plays a critical role in ferroptosis [40, 41] (Figure 5C).